SCHEMBL4721972

SCHEMBL4721972

COc1ccc[c]c1Sc1cccc2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.41
MAPT P10636 3/20 0.41
IFNAR1 P17181 1/20 0.40
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
MAPK1 P28482 2/20 0.39
NPY1R P25929 1/20 0.39
NPY2R P49146 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
HAO1 Q9UJM8 1/20 0.36
NQO1 P15559 1/20 0.36
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
DHFR P00374 2/20 0.35
RAD52 P43351 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4722941 0.84 IFNAR1 (0.40) MAPTIFNAR1ALDH1A1LMNAMAPK1
SCHEMBL4724534 0.82 HTR1B (0.44) IFNAR1SLC6A4
SCHEMBL4765333 0.81 HTR1B (0.47) L3MBTL1SLC6A4
SCHEMBL18065342 0.80 IFNAR1 (0.46) MAPTIFNAR1ALDH1A1LMNAMAPK1
SCHEMBL9018821 0.80 IFNAR1 (0.50) BRAFMAPTIFNAR1ALDH1A1LMNA
SCHEMBL4720824 0.76 CA1 (0.41) MAPTALDH1A1MAPK1SMN1; SMN2MEN1
SCHEMBL16581498 0.74 IFNAR1 (0.41) MAPTIFNAR1ALDH1A1LMNAMAPK1
SCHEMBL7084083 0.72 MAPT (0.47) MAPTALDH1A1SMN1; SMN2MEN1RAB9A
SCHEMBL16581510 0.72 ALDH1A1 (0.36) MAPTALDH1A1LMNAMAPK1MEN1
SCHEMBL653427 0.70 IFNAR1 (0.42) MAPTIFNAR1ALDH1A1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 BRAF 4247/4885MAPT 4361/4885IFNAR1 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.